Moshe Ornstein is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 247 publications with 2,473 citations (h-index 27); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave # Ca-60
Cleveland, OH 441950001
Telephone
216-445-6592Provider last certified this registry record 20 Jul 2020.
Clinical trials
- Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Sponsor: Case Comprehensive Cancer Center
- Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Sponsor: Case Comprehensive Cancer Center
- Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20254 payments$18,394openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year20254 payments
- Eisai Inc.Program year20249 payments$14,705openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68.1%Kinase inhibitor23.5%Cabometyx36%Inlyta35%Lenvima19%Everolimus5%Fotivda5%Part D<11 patientsCytochrome P450 17A1 Inhibitor14.3%Abiraterone Acetate100%Part D≥32 patients+ 4 more classes in this area
Metabolism & gastrointestinal
16.9%Corticosteroid14.5%Prednisone100%Part D≥48 patientsSerotonin-3 Receptor Antagonist1.4%Ondansetron Hcl100%Part D<11 patients+ 1 more class in this area
Nervous system
4.7%Central Nervous System Stimulant2.2%Methylphenidate Hcl100%Part D<11 patientsSNRI1.4%Venlafaxine Hcl Er100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).
Journal of Clinical Oncology
2023 - Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
Journal for ImmunoTherapy of Cancer
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”